Montpellier-based biotech company SeqOne has secured €20 million in an oversubscribed growth round to accelerate its AI-driven genomics software used in oncology and rare disease diagnostics.
The round was led by Supernova Invest, with continued support from existing backers Elaia, Omnes, and Mérieux Equity Partners.
Fueling global growth and U.S. launch
The fresh capital will enable SeqOne to expand its international footprint, enhance its software capabilities, and strengthen its presence in the U.S. healthcare market. The company recently launched a HIPAA-compliant platform to support U.S. laboratories, a strategic move as it targets broader adoption across North America.
CEO Martin Dubuc noted that the raise reflects confidence in SeqOne’s platform and vision. “This capital injection empowers us to scale our international operations, enhance our tech leadership, and remain a reliable long-term partner for our clients.”
Advertisement
110,000 patient analyses expected in 2025
The startup works with over 140 labs across 22 countries and expects to conduct over 110,000 genetic analyses this year. Its acquisition of Life & Soft earlier in 2025 extended its capabilities into multi-omics, expanding its reach into broader biological data analysis.
Earlier this month, SeqOne introduced SomaHemato, a haematology tool for identifying IGHV mutational status in chronic lymphocytic leukaemia (CLL), continuing its push to develop niche diagnostic tools for personalized medicine.
Empowering molecular labs through AI
Founded to modernize NGS analysis workflows, SeqOne offers an AI-based platform that simplifies genetic data interpretation for labs. Its software automates complex bioinformatics processes, supporting clinical decisions and enhancing diagnostic accuracy in cancer and rare disease cases.
With this new funding round, SeqOne aims to become the go-to provider of AI-powered genomic analysis software across Europe and the U.S.
Backers betting on precision medicine
Supernova Invest’s Rémi Spagnol emphasized that SeqOne’s technology is “exceptionally well-positioned” to lead a fast-growing global market. The firm joins a group of prominent investors that includes Elaia, Omnes, and Mérieux Equity Partners — all experienced backers of frontier biotech and AI innovations.
The round underscores increasing investor appetite for healthtech platforms that bridge the gap between genomics and actionable clinical outcomes through automation and AI.
